Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1656-1664

  Shibuya, Hidenobu ^a   Hamamura, Kazunori ^a   Hotta, Hiroshi ^a   Matsumoto, Yasuyuki ^a   Nishida, Yoshihiro ^a   Hattori, Hisashi ^a   Furukawa, Keiko ^a,b   Ueda, Minoru ^a   Furukawa, Koichi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHUBU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FOCAL ADHESION KINASE; GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GD3 SYNTHASE; PAXILLIN; PROTEIN P130; SYNTHETASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; LIPID ANALYSIS; MOLECULARLY TARGETED THERAPY; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WOUND HEALING;

BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CRK-ASSOCIATED SUBSTRATE PROTEIN; FOCAL ADHESION KINASE 1; GANGLIOSIDES; GENE EXPRESSION; GENE SILENCING; HUMANS; OSTEOSARCOMA; PAXILLIN; PHOSPHORYLATION; SIALYLTRANSFERASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TYROSINE;

EID: 84865713189     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02344.x     Document Type: Article

References (44)

1. Sweetnam R. Osteosarcoma. Br J Hosp Med 1982; 28: 112-21.
2. Regezi JA, Zarbo RJ, McClatchey KD, Courtney RM, Crissman JD. Osteosarcomas and chondrosarcoma of the jaws: immunohistochemical correlations. Oral Surg Oral Med Oral Pathol 1987; 64: 302-7.
3. August M, Magennis P, Dewitt D. Osteogenic sarcoma of the jaws: factors influencing prognosis. Int J Oral Maxillofac Surg 1997; 26: 198-204.
4. Patel SG, Meyers P, Huvos AG et al. Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer 2002; 95: 1495-503.
5. Russ JE, Jesse RH. Management of osteosarcoma of the maxilla and mandible. Am J Surg 1980; 140: 572-6.
6. Garrington GE, Scofield HH, Cornyn J, Hooker SP. Osteosarcoma of the jaws. Analysis of 56 cases. Cancer 1967; 20: 377-91.
7. Clark JL, Unni KK, Dahlin DC, Devine KD. Osteosarcoma of the jaw. Cancer 1983; 51: 2311-6.
8. Wiegandt H. Gangliosides. In: Wiegandt H, eds. Glycolipids. New York: Elsevier, 1985; 199-260.
9. Hakomori S, Igarashi Y. Gangliosides and glycosphingolipids as modulators of cell growth, adhesion, and transmenbrane signaling. Adv Lipid Res 1993; 25: 147-62.
10. Furukawa K, Lloyd KO. Gangliosides in melanoma. In:Ferrone S, ed. HumanMelanoma: From Basic Research to Clinical Application. Heidelberg: Springer, 1990; 15-30.
11. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985; 45: 2642-9.
12. Okada M, Furukawa K, Yamashiro S et al. High expression of ganglioside GD3 synthase gene in adult T cell leukemia cells unrelated to the gene expression of human T lymphotropic virus type I. Cancer Res 1996; 56: 2844-8.
13. Yoshida S, Fukumoto S, Kawaguchi H, Sato S, Ueda D, Furukawa K. Ganglioside GD2 in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 2001; 61: 4244-52.
14. Yamada T, Bando H, Takeuchi S et al. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasisproduced by GM2-expressing small-cell lung cancer cells. Cancer Sci 2011; 102: 2157-63.
15. Houghton AN, Mintzer D, Cordon-Cardo C et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985; 82: 1242-6.
16. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007; 25: 67-77.
17. Forero A, Shah J, Carlisle R et al. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm 2006; 21: 561-8.
18. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987; 47: 1098-104.
19. Fukuda M, Horibe K, Furukawa K. Enhancement of in vitro and in vivo antitumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. Int J Mol Med 1998; 2: 471-5.
20. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res 1998; 58: 2844-9.
21. Kushner BH, Kramer K, Modak S, Cheung NK. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase Istudy. J Clin Oncol 2011; 9: 1168-74.
22. Basak S, Birebent B, Purev E et al. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother 2003; 52: 145-54.
23. Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118: 6050-6.
24. Furukawa K, Akagi T, Nagata Y et al. GD2 ganglioside on human T-lymphotropic virus type I-infected T cells: possible activation of β-1, 4-N-acetylgalactosaminyltransferase gene by p40tax. Proc Natl Acad Sci USA 1993; 90: 1972-6.
25. Heiner JP, Miraldi F, Kallick S et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 1987; 47: 5377-81.
26. Hamamura K, Furukawa K, Hayashi T et al. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acad Sci USA 2005; 102: 11041-6.
27. Hamamura K, Tsuji M, Nakashima H et al. Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells. Biochim Biophys Acta 2008; 1780: 513-9.
28. Dong Y, Ikeda K, Hamamura K et al. GM1/GD1b/GA1 synthase expression results in the reduced cancer phenotypes with modulation of composition and raft-localization of gangliosides in a melanoma cell line. Cancer Sci 2010; 101: 2039-47.
29. Ohkawa Y, Miyazaki S, Hamamura H et al. Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains. J Biol Chem 2010; 285: 27213-23.
30. Hamamura K, Tsuji M, Hotta H et al. Functional activation of Src family kinase Yes is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3. J Biol Chem 2011; 286: 18526-37.
31. Hakomori S. Tumor-associated glycolipid antigens, their metabolism and organization. Chem Phys Lipids 1986; 42: 209-33.
32. Kannagi R. Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer. Glycoconj J 1997; 14: 577-84.
33. Cazet A, Lefebvre J, Adriaenssens E et al. GD synthase expression enhances proliferation and tumor growth of MDA-MB-231 breast cancer cells through c-Met activation. Mol Cancer Res 2010; 8: 1526-35.
34. Tsuchida A, Okajima T, Furukawa K et al. Synthesis of disialyl Lewis a structure in colon cancer cell lines by a sialyltransferase ST6GalNAc VI responsible for the synthesis of a-series gangliosides. J Biol Chem 2003; 278: 22787-94.
35. Satoh M, Nejad FM, Ohtani H et al. Association of renal cell carcinoma antigen, disialylgalactosylgloboside, with c-Src and Rho A in clustered domains at the surface membrane. Int J Oncol 2000; 16: 529-36.
36. Senda M, Ito A, Tsuchida A et al. Identification and expression of a sialyltransferase responsible for the synthesis of disialylgalactosylgloboside in normal and malignant kidney cells: down-regulation of ST6GalNAc VI in renal cancers. Biochem J 2007; 402: 459-70.
37. Haga Y, Hatanaka K, Hakomori SI. Effect of lipid mimetics of GM3 and lyso-GM3 dimer on EGF receptor tyrosine kinase and EGF-induced signal transduction. Biochim Biophys Acta 2008; 1780: 393-404.
38. Mitsuda T, Furukawa K, Fukumoto S, Miyazaki H, Urano T, Furukawa K. Over-expression of ganglioside GM1 results in the dispersion of platelet derived growth factor receptor from glycolipid-enriched microdomains and in the suppression of cell growth signals. J Biol Chem 2002; 277: 11239-46.
39. Zhang Q, Furukawa K, Chen H-H, Sakakibara T, Urano T, Furukawa K. Metastatic potential of mouse Lewis lung cancer cells is regulated via ganglioside GM1 by modulating the matrix metalloprotease-9 localization in lipid rafts. J Biol Chem 2006; 281: 18145-55.
40. Nishio M, Fukumoto S, Furukawa K et al. Over-expressed GM1 suppresses NGF signals by modulating the intra-cellular localization of NGF receptors and membrane fluidity in PC12 cells. J Biol Chem 2004; 279: 33368-78.
41. Inokuchi J. Physiopathological function of hematoside (GM3 ganglioside). Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 179-98.
42. Azuma K, Tanaka M, Uekita T et al. Tyrosine phos-phorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 2005; 24: 4754-64.
43. Mishra S, Joshi PG. Lipid raft heterogeneity: an enigma. J Neurochem 2007; 103(Suppl 1): 135-42.
44. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J 2004; 378: 281-92.